Mahamaya Lifesciences Limited
Bookbuilding IPO · BSE
- Price band
- ₹108 - ₹114
- Lot size
- 1,200 shares
- Issue amount
- ₹70.44 cr
- Total subscription
- 1.71×
- Opens
- 11 Nov 2025
- Closes
- 13 Nov 2025
- Allotment
- 14 Nov 2025
- Listing
- 18 Nov 2025
Offer at a glance
Issue overview
- Issue size
- 61,78,800 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,29,600
- Fresh issue
- ₹60.75 cr
- Offer for sale
- ₹6.16 cr
- Registrar
- Kfin Technologies Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,36,800
- Issue type
- Bookbuilding IPO
- Shares before issue
- 1,77,66,200
- Shares after issue
- 2,34,05,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,400 | ₹2,73,600 |
| sHNI | 3 | 3,600 | ₹4,10,400 |
| bHNI | 8 | 9,600 | ₹10,94,400 |
Share reservation
Subscription & GMP
Subscription by category
Reported 13 Nov 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 9 |
| NIB | 0 | 146 |
| RETAIL | 858 | 878 |
| HNIs(10L +) | 163 | 83 |
| HNIs (2-10L) | 82 | 63 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 13.41 | 15.98 |
| FIIs | 0 | 6.66 |
| Others | 0 | 9.32 |
| RETAIL | 23.47 | 24.02 |
| NIB | 10.05 | 40.07 |
| HNIs 2+ | 3.35 | 3.01 |
| HNIs 10+ | 6.7 | 37.06 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Jun-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 2.31 | 7.6 | 3.26 |
| ROE | 7.97 | 34.94 | 23.67 |
| ROCE | 7.3 | 23.15 | 16.16 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 15.65 | 0 |
| POST IPO(PE) | 16.25 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Mahamaya Lifesciences Limited | 0 | 0 | 0 | 27.82 | 26.19 | 7.60 |
| Nova Agritech Limited | 16.93 | 0 | 0 | 23.76 | 12.47 | 3.05 |
| Bhagiradha Chemicals & Industries Ltd | 247.63 | 0 | 0 | 52.61 | 2.03 | 1.14 |
Company information
Company profile
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts designed to enhance soil and crop health. The company specializes in pesticide formulations and supplies bulk products to leading Indian agrochemical players as well as multinational corporations (MNCs). Mahamaya imports global research-based molecules, registers them with the Central Insecticides Board, and markets both technical and value-added formulations. The company has invested significantly in global registrations and currently exports to markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey. Its portfolio spans bulk formulations, technical grade molecules, branded products, and export-focused formulations.
Strengths
- Experienced Leadership: Managed by a skilled team with deep expertise in agrochemicals, R&D, exports, and regulatory affairs, driving strategic and operational efficiency.
- Comprehensive Product Range: Diverse lineup of insecticides, herbicides, fungicides, and bioproducts across technical, branded, and export formats ensures wide market presence.
- Robust R&D and Regulatory Strength: Strong capability in molecule discovery and registration with Indian and global authorities enhances innovation, compliance, and market expansion potential.
Risk factors
- High Customer Dependence: The company’s revenue relies heavily on a limited number of clients, with the top 10 customers contributing 71.35%, 76.26%, 83.14%, and 71.12% of total sales for the quarter ended June 30, 2025, and fiscal years 2025, 2024, and 2023, respectively, reflecting a notable concentration risk.
- Absence of Long-Term Agreements: The company operates without long-term contracts with customers or suppliers, exposing it to potential fluctuations in demand, pricing, and supply continuity.
- Volatility in Raw Material Costs: As raw materials constitute a significant portion of total expenses, any increase in prices or disruption in availability could adversely affect profitability and operational stability.
Promoters
Mr. Krishnamurthy Ganesan
Mrs. Lalitha Krishnamurthy
Mr. Prashant Krishnamurthy
Registrar & documents
Lead manager
Oneview Corporate Advisors Private Limited
Registrar & contacts
Kfin Technologies Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Unit No: DPT – 033, Ground Floor, Plot No: 79 – 80, DLF Prime Tower, Block, Okhla, Phase – 1 Delhi, New Delhi, 110020
+91-1146561474
[email protected]Company website ↗Understanding MAHALIFE IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.